SAFETY AND IMMUNOGENICITY OF A NATIONAL COMBINED VACCINE AGAINST PERTUSSIS, DIPHTHERIA, TETANUS, HEPATITIS B AND Hib-INFECTION, CON- TAINING ACELLULAR PERTUSSIS COMPONENT, DURING IMMUNIZATION OF ADULTS

Study safety, reactogenicity and immunologic effectiveness of a national combined vaccine against diphtheria, pertussis (acellular component), tetanus, hepatitis B and Hib-infection during immunization of volunteers aged 18-60 years.
MATERIALS AND METHODS:
The study was carried out in accordance with ethical standards and requirements, regulated by Helsinki declaration and Good clinical practice (ICHGCP). In a simple non-randomized clinical trial 20 adult volunteers took part, the mean age of those was 46.9 years.
RESULTS:
Registered: post-vaccination reactions (both local and systemic) were mild and of moderate degree of severity, stopped independently after 2-3 days without administration of drug treatment. Postvaccinal complications were not noted. Parameters of general and biochemical analysis of blood, urine, IgE content in dynamics of immunization were within normal limits. A single administration of aAPDT–HepB+Hib to individuals aged 18-60 years resulted in development of antibodies against all the components of the preparation. Seroconversion factor fluctuated from 6.9 to 53.5:
CONCLUSION:
The results obtained allow to recommend the vaccine for evaluation of its safety, reactogenicity, immunologic and prophylaxis effectiveness in randomized clinical observation trials in children.

Authors:Feldblyum IV, Nikolaeva AM, Pavroz KA, Danilina TV, Sosnina OY, Vyaznikova TV, Ershov AE, Trofimov DM, Polushkina AV.
Journal:bstractSend to:
Zh Mikrobiol Epidemiol Immunobiol. 2016
Link:http://www.ncbi.nlm.nih.gov/pubmed/27029116